Patents by Inventor Marie Eskling

Marie Eskling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Formulation of growth hormone albumin-binder conjugate
    Patent number: 11045523
    Abstract: The present invention relates to compositions of growth hormone albumin-binder conjugates including pharmaceutical formulations. The compositions are able to provide initial and long term stability of the growth hormone albumin-binder conjugate, rendering such compositions suited for use as a pharmaceutical formulation.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: June 29, 2021
    Assignee: NOVO NORDISK HEALTHCARE AG
    Inventors: Jette Nielsen, Marie Eskling, Stina Granzau Christensen
  • Growth Hormone Compound Formulation
    Publication number: 20160058879
    Abstract: The present inventions relates to compositions of growth hormone compounds, including pharmaceutical formulations. The compositions are able to provide initial and long term stability of the growth hormone compounds, rendering such compositions suited for use as a pharmaceutical formulation.
    Type: Application
    Filed: April 4, 2014
    Publication date: March 3, 2016
    Inventors: Jette Nielsen, Marie Eskling, Stina Granzau Christensen, Michael Hoejby, Minna Braendholt Olsen
  • Immunogenic HER-2 variants
    Patent number: 8022039
    Abstract: The present invention provides for a novel method for purification of EGFR family proteins obtained from cultures of insect cells. The process comprises subsequent steps of a) diafiltration and exchange of culture medium with buffer, b) immobilized metal affinity chromatography (IMAC), C) size exclusion chromatography (SEC), and d) anion exchange chromatography (AIE). The method also provides for an immunogenic variant of HER-2 protein which for which the purification process has been especially adapted, as well as means for the preparation of the variant.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: September 20, 2011
    Assignee: BN ImmunoTherapeutics, Inc.
    Inventors: Marie Eskling, Klaus Gregorius Nielsen
  • PURIFICATION OF HER-2 VARIANTS
    Publication number: 20100285071
    Abstract: The present invention provides for a novel method for purification of EGFR family proteins obtained from cultures of insect cells. The process comprises subsequent steps of a) diafiltration and exchange of culture medium with buffer, b) immobilized metal affinity chromatography (IMAC), C) size exclusion chromatography (SEC), and d) anion exchange chromatography (AIE). The method also provides for an immunogenic variant of HER-2 protein which for which the purification process has been especially adapted, as well as means for the preparation of the variant.
    Type: Application
    Filed: June 28, 2010
    Publication date: November 11, 2010
    Inventors: MARIE ESKLING, Klaus Gregorius Nielsen
  • Purification of HER-2 variants
    Patent number: 7763452
    Abstract: The present invention provides for a novel method for purification of EGFR family proteins obtained from cultures of insect cells. The process comprises subsequent steps of a) diafiltration and exchange of culture medium with buffer, b) immobilized metal affinity chromatography (IMAC), c) size exclusion chromatography (SEC), and d) anion exchange chromatography (AIE). The method also provides for an immunogenic variant of HER-2 protein for which the purification process has been especially adapted, as well as means for the preparation of the variant.
    Type: Grant
    Filed: June 24, 2004
    Date of Patent: July 27, 2010
    Assignee: BN Immunotherapeutics, Inc.
    Inventors: Marie Eskling, Klaus Gregorius Nielsen
  • Purification of her-2 variants
    Publication number: 20060240511
    Abstract: The present invention provides for a novel method for purification of EGFR family proteins obtained from cultures of insect cells. The process comprises subsequent steps of a) diafiltration and exchange of culture medium with buffer, b) immobilized metal affinity chromatography (IMAC), c) size exclusion chromatography (SEC), and d) anion exchange chromatography (AIE). The method also provides for an immunogenic variant of HER-2 protein which for which the purification process has been especially adapted, as well as means for the preparation of the variant.
    Type: Application
    Filed: June 24, 2004
    Publication date: October 26, 2006
    Applicant: PHARMEXA A/S
    Inventors: Marie Eskling, Klaus Nielsen